Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIMM Study: Plasmid AMEP in Metastatic Melanoma
NCT01764009Phase 2Withdrawn
- Sponsor
- Valerio Therapeutics
- Start
- Jun 2012
- Primary completion
- Dec 2013
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 2
01
Overview
A Phase 2 trial of plasmid AMEP in melanoma, sponsored by Valerio Therapeutics. Planned start Jun 2012; status: withdrawn.
02
Drugs
plasmid AMEP
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01764009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01764009.